William Blair Begins Coverage on Sensei Biotherapeutics (NASDAQ:FTH)

Analysts at William Blair assumed coverage on shares of Sensei Biotherapeutics (NASDAQ:FTH) in a research report issued on Friday, Briefing.com reports. The firm set an “outperform” rating on the stock.

Other research analysts also recently issued research reports about the stock. Oppenheimer assumed coverage on shares of Sensei Biotherapeutics in a report on Tuesday, July 28th. They issued an “outperform” rating and a $60.00 price target for the company. JonesTrading began coverage on Sensei Biotherapeutics in a research note on Tuesday, August 4th. They set a “buy” rating and a $55.00 price objective on the stock. Guggenheim started coverage on Sensei Biotherapeutics in a research note on Wednesday, September 16th. They set a “buy” rating and a $70.00 price objective on the stock. TD Cowen started coverage on Sensei Biotherapeutics in a research report on Wednesday, September 9th. They set a “buy” rating on the stock. Finally, Robert W. Baird assumed coverage on Sensei Biotherapeutics in a research report on Friday, June 26th. They set an “outperform” rating and a $57.00 price objective on the stock. Two equities research analysts have rated the stock with a Strong Buy rating, twelve have assigned a Buy rating, one has given a Hold rating and one has assigned a Sell rating to the company’s stock. According to data from MarketBeat.com, the stock presently has a consensus rating of “Moderate Buy” and a consensus price target of $56.25.

Sensei Biotherapeutics Trading Up 3.0%

Sensei Biotherapeutics stock opened at $20.60 on Friday. The stock has a market capitalization of $532.30 million, a P/E ratio of -0.15 and a beta of -0.29. The company’s fifty day simple moving average is $31.50. Sensei Biotherapeutics has a 52-week low of $7.45 and a 52-week high of $42.14.

Sensei Biotherapeutics (NASDAQ:FTH) last issued its quarterly earnings data on Tuesday, August 4th. The company reported ($2.84) EPS for the quarter, topping analysts’ consensus estimates of ($5.04) by $2.20. As a group, sell-side analysts anticipate that Sensei Biotherapeutics will post -13.69 EPS for the current year.

Institutional Trading of Sensei Biotherapeutics

Several institutional investors have recently added to or reduced their stakes in FTH. Vivo Capital LLC purchased a new position in shares of Sensei Biotherapeutics during the first quarter valued at approximately $22,758,000. Stempoint Capital LP bought a new position in shares of Sensei Biotherapeutics during the first quarter valued at approximately $4,188,000. Alyeska Investment Group L.P. bought a new position in shares of Sensei Biotherapeutics during the second quarter valued at approximately $3,610,000. Bank of America Corp DE raised its holdings in shares of Sensei Biotherapeutics by 10,692.5% in the first quarter. Bank of America Corp DE now owns 33,025 shares of the company’s stock worth $1,041,000 after buying an additional 32,719 shares during the period. Finally, Renaissance Technologies LLC raised its holdings in shares of Sensei Biotherapeutics by 178.2% in the first quarter. Renaissance Technologies LLC now owns 32,041 shares of the company’s stock worth $1,010,000 after buying an additional 20,525 shares during the period. Institutional investors own 10.50% of the company’s stock.

About Sensei Biotherapeutics

Sensei Biotherapeutics, Inc is a clinical-stage biotechnology company focused on developing cancer immunotherapies designed to activate the immune system against tumors. The company’s approach is intended to address immune suppression within the tumor microenvironment and potentially improve patients’ responses to existing cancer treatments.

Sensei’s pipeline has included antibody-based and vaccine-based immunotherapies. Its lead programs have included SNS-101, an antibody designed to target the VISTA immune checkpoint, and earlier ImmunoPhage-based programs intended to stimulate tumor-specific immune responses.